articleTop 10% cited
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Clinical Cancer Research · 2007 · Vol. 13(7) · pp. 2151–2157
Takeo Nomi✉Masayuki ShoTakahiro AkahoriKaoru HamadaAtsushi Kubo(Nara Medical University)Hiromichi KanehiroShinji NakamuraKoji EnomotoHideo Yagita∥(Juntendo University)Miyuki Azuma(Tokyo Medical and Dental University)Yoshiyuki Nakajima
Abstract
Our data suggest for the first time that PD-L1 status may be a new predictor of prognosis for patients with pancreatic cancer and provide the rationale for developing a novel therapy of targeting the PD-L/PD-1 pathway against this fatal disease.
Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchPhagocytosis and Immune RegulationPancreatic cancerPD-L1MedicineCancer researchImmune systemCancerGemcitabineMonoclonal antibodyCD8Immunohistochemistry
MeSH terms
GemcitabineAdenocarcinomaAgedAnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineFemaleHumansImmunohistochemistryMaleMice, Inbred C57BLMiddle AgedPancreatic NeoplasmsPeptides
Citations
895
FWCI
8.26
field-weighted impact
References
31
Percentile
98%
vs. same field & year
Citations per year
Cited by
PD-1 and Its Ligands in Tolerance and Immunity
Annual Review of Immunology · 2008 · 5,272 citations
Prognostic and predictive value of PDL1 expression in breast cancer
Oncotarget · 2014 · 496 citations
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Journal of Cellular Physiology · 2018 · 506 citations
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Oncotarget · 2017 · 415 citations
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Clinical Cancer Research · 2009 · 812 citations
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Clinical Cancer Research · 2015 · 774 citations
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
The Journal of Experimental Medicine · 2009 · 2,023 citations
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
Breast Cancer Research and Treatment · 2014 · 577 citations
References
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
The EMBO Journal · 1992 · 3,162 citations
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine · 1999 · 2,463 citations
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine · 2002 · 4,970 citations
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Nature Immunology · 2001 · 2,931 citations
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
The Journal of Experimental Medicine · 2000 · 5,184 citations
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Clinical Cancer Research · 2005 · 789 citations
Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
Cancer Research · 2005 · 998 citations
THE B7 FAMILY REVISITED
Annual Review of Immunology · 2005 · 2,279 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.